| Oct 17 |
Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
|
| Oct 17 |
Merck (MRK): Promising Long-Term Stock with Strategic Acquisitions
|
| Oct 16 |
Merck posts positive trial data for Capvaxive pneumonia vaccine in at-risk adults
|
| Oct 16 |
Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease
|
| Oct 15 |
Novocure Shoots Skyward, Reversing Setbacks, After FDA Approves Lung Cancer Treatment
|
| Oct 15 |
Merck (MRK) Rises As Market Takes a Dip: Key Facts
|
| Oct 15 |
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
|
| Oct 14 |
Exelixis & Merck sign development collaboration for head, neck cancer treatment and renal cell carcinoma
|
| Oct 14 |
erck & Co. (MRK): Winrevair Approval Drives Cardiovascular Growth
|
| Oct 14 |
Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma
|
